What is Tesamorelin?
Tesamorelin is a synthetic GHRH analog with FDA approval (Egrifta®) for HIV-associated lipodystrophy. It stimulates natural growth hormone release with well-documented effects on visceral fat reduction.
The 20mg vial is the top of the Tesamorelin ladder — 10-20 days of research from a single reconstitution, and the smallest draw volumes of any size in the range.
Quick Reference
| Parameter | Value |
|---|---|
| Peptide Amount | 20mg |
| Recommended BAC Water | 2mL |
| Resulting Concentration | 10mg/mL |
| Typical Research Dose | 1-2mg |
| Frequency | Once daily |
| Research Duration | 12-26 weeks |
Reconstitution Guide
Concentration Calculations
With 20mg in 2mL BAC water:
- Concentration: 10mg/mL = 10000mcg/mL
- Per unit (U-100): 100mcg per unit
Holding the diluent at 2mL keeps the whole vial in play for the standard 1-2mg range while cutting the injected volume to a tenth of what the 2mg vial requires at the same dose. Larger diluent volumes are possible but push the reconstituted solution past its useful window before the vial is finished.
Dosage Protocol
Common Dose Calculations
| Desired Dose | Draw Volume | Syringe Units |
|---|---|---|
| 1mg | 0.10mL | 10 units |
| 1.5mg | 0.15mL | 15 units |
| 2mg | 0.20mL | 20 units |
Doses Per Vial
| Daily Dose | Doses | Duration |
|---|---|---|
| 1mg | 20 doses | 20 days |
| 2mg | 10 doses | 10 days |
At 1mg daily the vial runs 20 days, which still sits inside the 3-4 week reconstituted window — no wasted material.
Why Choose 20mg
| Factor | 10mg Vial | 20mg Vial |
|---|---|---|
| Doses at 2mg | 5 | 10 |
| Cost per dose | Lower | Lowest |
| Reconstitutions | Every 5 days | Every 10 days |
| Injection volume | 0.40mL at 2mg | 0.20mL at 2mg |
| Best for | Extended protocols | Full-length protocols |
Suggested Protocol
Standard (FDA-based):
- Dose: 2mg
- Frequency: Once daily
- Timing: Morning, fasted
- Duration: 12-26 weeks
Storage Requirements
| Form | Temperature | Duration |
|---|---|---|
| Lyophilized | -20°C | 2+ years |
| Reconstituted | 2-8°C | 3-4 weeks |
Research Considerations
Mechanism of Action
- GHRH receptor activation — Pituitary stimulation
- Pulsatile GH release — Natural pattern
- IGF-1 elevation — Secondary effect
- Visceral fat effects — Primary research focus
Clinical Validation
FDA-approved studies demonstrated:
- Significant visceral fat reduction
- Improved trunk fat distribution
- Maintained IGF-1 within normal range
- Well-characterized safety profile
Sourcing for Research
Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.